ASTCT Pharmacy SIG Journal Club - March 2024

The ASTCT Pharmacy SIG March 2024 Journal Club will air on Wednesday, March 27, 2024 at 2 pm CDT/3 pm EDT. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the March Journal Club session, Drs. Anderson and Boucher will present on two articles related to (a) motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma and (b) recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving CAR T-cell therapy. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

Presenters & Articles

Mallori Anderson, PharmD

PGY-2 Pharmacy Resident

WVU Medicine

Article: Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Julie L. Boucher, PharmD, BCPS

PGY-2 Pharmacy Resident

Yale New Haven Hospital

Article: Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Describe the effect of bendamustine on chimeric antigen receptor (CAR) efficacy.
2. Analyze the efficacy outcomes for patients receiving bendamustine before apheresis versus bendamustine naive.
3. Discuss the safety outcomes related to bendamustine exposure after CAR T-cell therapy, and the impact of prior bendamustine exposure on CAR T-cell expansion.
4. Review HSC mobilization regimens available for autologous transplantation in multiple myeloma patients.
5. Describe the mechanism of action of motixafortide and Granulocyte-Colony Stimulating Factor (G-CSF) to mobilize HSCs. 
6. Evaluate the efficacy and safety of motixafortide and G-CSF compared to plerixafor and G-CSF.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity, UAN # JA0007204-9999-24-020-L01-P qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full CE information for this session can be found here.